公开(公告)号：US20180099957A1

公开(公告)日：2018-04-12

申请号：US15724919

申请日：2017-10-04

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jun Ma ,  Guoqiang Wang ,  Bin Wang ,  Xuechao Xing ,  Ruichao Shen ,  Jing He ,  Yat Sun Or

IPC: C07D413/14 ,  C07D413/12 ,  C07D261/08

CPC classification number: C07D413/14 ,  C07D261/08 ,  C07D413/12 ,  C07D417/14

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US20160289262A1

公开(公告)日：2016-10-06

申请号：US15085800

申请日：2016-03-30

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Ruichao Shen ,  Xuechao Xing ,  Jiang Long ,  Peng Dai ,  Brett Granger ,  Jing He

IPC: C07J43/00 ,  C07J41/00

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

Abstract translation: 本发明还提供包含这些化合物的药物组合物和使用该化合物治疗FXR介导的或TGR5介导的疾病或病症的方法。

公开(公告)号：US20160145296A1

公开(公告)日：2016-05-26

申请号：US14952526

申请日：2015-11-25

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Ruichao Shen ,  Peng Dai ,  Jiang Long ,  Xuechao Xing ,  Guoqiang Wang

IPC: C07J43/00 ,  C07J31/00 ,  C07J9/00 ,  C07J41/00

CPC classification number: C07J43/003 ,  A61P1/16 ,  C07J9/00 ,  C07J9/005 ,  C07J17/00 ,  C07J31/006 ,  C07J41/0055 ,  C07J41/0061 ,  C07J41/0088 ,  C07J41/0094 ,  C07J51/00

Abstract: The present invention relates to compounds of Formula (IA) and Formula (IB), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.

Abstract translation: 本发明涉及式（IA）和式（IB）的化合物及其药学上可接受的盐，其中R1，R2，R3，R4，R5，R6，R7，R8，R9和m如本文所定义，药物组合物 包括这些化合物和这些化合物用于治疗TGR5介导的疾病或病症的方法。